Clinical Trials

Phase 2 Active not recruiting

Multiple Myeloma

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

160 enrolled

Phase 3 Active not recruiting

Neoplasms, Plasma Cell

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Multiple Myeloma

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

232 enrolled

CNS

Ependymoma, Medulloblastoma, Recurrence

NCT02844309 2026-02-11

BDH-WM02

Phase 4 Completed

44 enrolled

Waldenstrom Macroglobulinemia

NCT02858804 2026-02-11

BDH-MCL01

Phase 4 Completed

55 enrolled

Phase 3 Active not recruiting

Lymphoma, Mantle-Cell

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Phase 2/3 Not yet recruiting

Multiple Myeloma

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06530576 2025-11-18

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

Phase 2 Recruiting

48 enrolled

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT00769587 2025-09-22

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed

MyeloidOther neoplasm

Precancerous Conditions, Mastocytosis, Systemic

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Phase 2 Active not recruiting

50 enrolled

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 1 FDA

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

1,085 enrolled 22 charts 1 FDA

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

256 enrolled 13 charts

Multiple Myeloma

NCT02507336 2024-08-01

Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

2 enrolled 5 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2 Terminated

17 enrolled

Multiple Myeloma, Renal Insufficiency

NCT02586038 2024-05-08

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

175 enrolled

Multiple Myeloma

NCT02891811 2024-03-29

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

124 enrolled

Multiple Myeloma

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT00019539 2024-03-04

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Other hematologic neoplasm

Genitourinary

Carcinoma, Renal Cell, Neoplasms, Urologic Neoplasms

NCT06256627 2024-02-13

The Maintenance Treatment of "ITIVA" in AML Patients

Phase NA Recruiting

130 enrolled

Leukemia, Myeloid, Acute

NCT01661400 2024-01-31

ASCR

Phase 1 Completed

14 enrolled

CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Medulloblastoma, Wilms Tumor, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive

NCT06017284 2023-11-24

PTCA199-5

Phase 3 Recruiting

100 enrolled

Gastrointestinal

Nausea, Pancreatic Neoplasms, Vomiting

NCT00020046 2023-10-31

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Genitourinary

Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT00777998 2023-10-27

Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma

221 enrolled

Multiple Myeloma

NCT00049673 2023-09-13

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

332 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03759093 2023-09-06

CURATE.AI Optimized Modulation for Multiple Myeloma

Phase 2/3 Unknown

20 enrolled

Multiple Myeloma

NCT01063179 2023-06-29

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

511 enrolled

Multiple Myeloma

NCT04941937 2023-02-27

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

90 enrolled

Multiple Myeloma

NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Phase 2 Terminated

5 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00054158 2022-10-03

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

24 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01849783 2022-05-11

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

41 enrolled 12 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT05266820 2022-03-18

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

120 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02424851 2022-01-27

OPTIMAL

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01125176 2022-01-21

ThRiL

LymphoidOther hematologic neoplasm

15 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00075829 2021-11-01

BMT CTN 0102

710 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112502 2021-10-18

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

178 enrolled 23 charts

CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT00025285 2021-09-09

Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

46 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00049361 2021-09-09

Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

CNS

Brain Neoplasms, Central Nervous System Neoplasms

NCT00079092 2021-09-09

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

18 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT02128230 2021-06-22

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Phase 2 Terminated

20 enrolled 7 charts

Multiple Myeloma

NCT00538733 2021-05-24

T-BiRD

26 enrolled 16 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Phase 1/2 Unknown

48 enrolled

Multiple Myeloma

NCT02545907 2021-04-15

CATALYST

Phase 1/2 Completed

10 enrolled 14 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

264 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04382300 2021-01-28

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00966693 2020-11-04

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

77 enrolled 19 charts